197 related articles for article (PubMed ID: 37688978)
1. Disruption of the Keap1-mTORC2 axis by cancer-derived Keap1/mLST8 mutations leads to oncogenic mTORC2-AKT activation.
Chen Y; Jiao D; He H; Sun H; Liu Y; Shi Q; Zhang P; Li Y; Mo R; Gao K; Wang C
Redox Biol; 2023 Nov; 67():102872. PubMed ID: 37688978
[TBL] [Abstract][Full Text] [Related]
2. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling.
Wang B; Jie Z; Joo D; Ordureau A; Liu P; Gan W; Guo J; Zhang J; North BJ; Dai X; Cheng X; Bian X; Zhang L; Harper JW; Sun SC; Wei W
Nature; 2017 May; 545(7654):365-369. PubMed ID: 28489822
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the Scaffolding Function of mLST8 Selectively Inhibits mTORC2 Assembly and Function and Suppresses mTORC2-Dependent Tumor Growth
Hwang Y; Kim LC; Song W; Edwards DN; Cook RS; Chen J
Cancer Res; 2019 Jul; 79(13):3178-3184. PubMed ID: 31085701
[TBL] [Abstract][Full Text] [Related]
4. Dynamic modelling of the PI3K/MTOR signalling network uncovers biphasic dependence of mTORC1 activity on the mTORC2 subunit SIN1.
Ghomlaghi M; Yang G; Shin SY; James DE; Nguyen LK
PLoS Comput Biol; 2021 Sep; 17(9):e1008513. PubMed ID: 34529665
[TBL] [Abstract][Full Text] [Related]
5. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.
Guertin DA; Stevens DM; Thoreen CC; Burds AA; Kalaany NY; Moffat J; Brown M; Fitzgerald KJ; Sabatini DM
Dev Cell; 2006 Dec; 11(6):859-71. PubMed ID: 17141160
[TBL] [Abstract][Full Text] [Related]
6. Identification of an adaptor protein that facilitates Nrf2-Keap1 complex formation and modulates antioxidant response.
Zhang Y; Hou Y; Liu C; Li Y; Guo W; Wu JL; Xu D; You X; Pan Y; Chen Y
Free Radic Biol Med; 2016 Aug; 97():38-49. PubMed ID: 27212020
[TBL] [Abstract][Full Text] [Related]
7. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
Shibata T; Ohta T; Tong KI; Kokubu A; Odogawa R; Tsuta K; Asamura H; Yamamoto M; Hirohashi S
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13568-73. PubMed ID: 18757741
[TBL] [Abstract][Full Text] [Related]
8. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism.
Chen CH; Kiyan V; Zhylkibayev AA; Kazyken D; Bulgakova O; Page KE; Bersimbaev RI; Spooner E; Sarbassov DD
J Biol Chem; 2013 Sep; 288(38):27019-27030. PubMed ID: 23928304
[TBL] [Abstract][Full Text] [Related]
9. The mTOR (mammalian target of rapamycin) kinase maintains integrity of mTOR complex 2.
Chen CH; Sarbassov dos D
J Biol Chem; 2011 Nov; 286(46):40386-94. PubMed ID: 21965657
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.
Tebay LE; Robertson H; Durant ST; Vitale SR; Penning TM; Dinkova-Kostova AT; Hayes JD
Free Radic Biol Med; 2015 Nov; 88(Pt B):108-146. PubMed ID: 26122708
[TBL] [Abstract][Full Text] [Related]
11. TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling.
Liu W; Zhao Y; Wang G; Feng S; Ge X; Ye W; Wang Z; Zhu Y; Cai W; Bai J; Zhou X
Redox Biol; 2022 Jul; 53():102344. PubMed ID: 35636015
[TBL] [Abstract][Full Text] [Related]
12. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
Zou Z; Chen J; Yang J; Bai X
Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
[TBL] [Abstract][Full Text] [Related]
13. Different Inhibition of Nrf2 by Two Keap1 Isoforms α and β to Shape Malignant Behaviour of Human Hepatocellular Carcinoma.
Chen F; Xiao M; Feng J; Wufur R; Liu K; Hu S; Zhang Y
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142252
[TBL] [Abstract][Full Text] [Related]
14. mLST8 Promotes mTOR-Mediated Tumor Progression.
Kakumoto K; Ikeda J; Okada M; Morii E; Oneyama C
PLoS One; 2015; 10(4):e0119015. PubMed ID: 25906254
[TBL] [Abstract][Full Text] [Related]
15. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination.
Hast BE; Goldfarb D; Mulvaney KM; Hast MA; Siesser PF; Yan F; Hayes DN; Major MB
Cancer Res; 2013 Apr; 73(7):2199-210. PubMed ID: 23382044
[TBL] [Abstract][Full Text] [Related]
16. DC32, a Dihydroartemisinin Derivative, Ameliorates Collagen-Induced Arthritis Through an Nrf2-p62-Keap1 Feedback Loop.
Fan M; Li Y; Yao C; Liu X; Liu J; Yu B
Front Immunol; 2018; 9():2762. PubMed ID: 30538709
[TBL] [Abstract][Full Text] [Related]
17. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
García-Martínez JM; Alessi DR
Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
Taguchi K; Motohashi H; Yamamoto M
Genes Cells; 2011 Feb; 16(2):123-40. PubMed ID: 21251164
[TBL] [Abstract][Full Text] [Related]
19. A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2.
Qiu L; Wang M; Zhu Y; Xiang Y; Zhang Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042301
[TBL] [Abstract][Full Text] [Related]
20. Directly interact with Keap1 and LPS is involved in the anti-inflammatory mechanisms of (-)-epicatechin-3-gallate in LPS-induced macrophages and endotoxemia.
Chiou YS; Huang Q; Ho CT; Wang YJ; Pan MH
Free Radic Biol Med; 2016 May; 94():1-16. PubMed ID: 26878775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]